Enovis (NYSE:ENOV - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.750-2.800 for the period, compared to the consensus EPS estimate of 2.710. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion.
Enovis Price Performance
Shares of ENOV traded up $3.58 during trading hours on Wednesday, reaching $46.89. 1,551,122 shares of the stock traded hands, compared to its average volume of 579,490. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Enovis has a 52-week low of $38.27 and a 52-week high of $65.03. The company's 50-day moving average price is $42.19 and its two-hundred day moving average price is $45.63. The company has a market cap of $2.62 billion, a P/E ratio of -28.25 and a beta of 1.91.
Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.03. The company had revenue of $525.20 million for the quarter, compared to the consensus estimate of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. Enovis's revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 EPS. On average, analysts anticipate that Enovis will post 2.7 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have issued reports on ENOV shares. Needham & Company LLC reduced their price target on shares of Enovis from $82.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. JMP Securities started coverage on shares of Enovis in a report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price target on the stock. Evercore ISI reduced their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. reduced their price target on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $67.00.
Read Our Latest Research Report on Enovis
Enovis Company Profile
(
Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
